Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction.
Biomarkers
Brain natriuretic peptide
Collagen
Echocardiography, Doppler
Heart failure, diastolic
Left ventricle
Systolic function
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
30
11
2020
received:
28
08
2020
accepted:
02
01
2021
pubmed:
13
2
2021
medline:
2
7
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
Biomarkers reflecting myocardial fibrosis and inflammation have been individually associated with left ventricular hypertrophy (LVH) and diastolic dysfunction (DD). However, the added value of a fibrosis-inflammation multimarker approach in a populational setting is yet to be studied. We evaluated the value of a multimarker approach to detect LVH and DD in a large population-based cohort. In a prespecified analysis (BioSe-PreIC study) of the 4th visit of the STANISLAS cohort (1705 subjects, 47 ± 14 years, 47.4% men), we evaluated the ability of brain natriuretic peptide (BNP), Galectin-3 (GAL3), N-terminal propeptide of procollagen type III (P3NP), and soluble ST2 to predict LVH (LV mass > 116/100 g/m As the measurement of Gal3, P3NP, and ST2 results in marginal (even if significant) increase in the prediction of DD/LVH on top of routine evaluation, their systematic use should not be promoted in unselected healthy individuals to screen for preclinical DD. Further research is needed to determine whether a more personalized medicine approach combing proteomic and clinical scoring can amplify the added value of biomarkers to identify preclinical DD.
Identifiants
pubmed: 33576580
doi: 10.1002/ehf2.13203
pmc: PMC8006620
doi:
Substances chimiques
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1700-1705Informations de copyright
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
J Am Heart Assoc. 2017 May 2;6(5):
pubmed: 28465299
Circ Heart Fail. 2011 May;4(3):246-56
pubmed: 21350055
Eur J Heart Fail. 2009 Feb;11(2):191-7
pubmed: 19168518
Am Heart J. 2010 Oct;160(4):721-8
pubmed: 20934567
Eur J Heart Fail. 2013 Oct;15(10):1095-101
pubmed: 23650131
J Am Coll Cardiol. 2017 Jun 27;69(25):3119-3121
pubmed: 28641802
JAMA. 2011 Aug 24;306(8):856-63
pubmed: 21862747
JACC Heart Fail. 2016 Apr;4(4):237-48
pubmed: 26682794
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239
pubmed: 23747642
Clin Chem. 2011 Jun;57(6):874-82
pubmed: 21515743
J Am Coll Cardiol. 2013 Jul 23;62(4):263-71
pubmed: 23684677
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
ESC Heart Fail. 2021 Apr;8(2):1700-1705
pubmed: 33576580
Int J Epidemiol. 2018 Apr 1;47(2):395-395j
pubmed: 29220499
J Card Fail. 2013 Mar;19(3):163-8
pubmed: 23482076
Circ Heart Fail. 2019 May;12(5):e005897
pubmed: 31104495
J Clin Lab Anal. 2018 Oct;32(8):e22574
pubmed: 29797353
Eur J Echocardiogr. 2009 Mar;10(2):165-93
pubmed: 19270053
Circulation. 2017 May 30;135(22):e1054-e1091
pubmed: 28446515
Circ Heart Fail. 2011 Nov;4(6):733-9
pubmed: 21900186